A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Trial Profile

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 15 Jun 2018 Results presented in a BeiGene media release.
    • 15 Jun 2018 According to a BeiGene media release, the company has received the results from an independent review board. Full results from this study are expected to be presented at an upcoming major medical conference.
    • 09 May 2018 According to a BeiGene media release, the company expects to submit the New drug application (NDA) in China in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top